Assessing CSL’s Valuation After US Tariff Reassurances And Manufacturing Expansion Plans

Simply Wall St.04-08

Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2625394136?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618","is_english":true,"pubTime":"2026-04-08 19:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625394136","market":"sg","top_or_hot":-1,"title":"Assessing CSL’s Valuation After US Tariff Reassurances And Manufacturing Expansion Plans","media":"Simply Wall St.","content":"<div>\n<p>Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-valuation-after-us-tariff-reassurances-and-ma\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing CSL’s Valuation After US Tariff Reassurances And Manufacturing Expansion Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing CSL’s Valuation After US Tariff Reassurances And Manufacturing Expansion Plans\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-08 19:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-valuation-after-us-tariff-reassurances-and-ma><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. ...</p>\n\n<a href=\"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-valuation-after-us-tariff-reassurances-and-ma\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7508","symbol_name":"医药生物股","start_time":0,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-valuation-after-us-tariff-reassurances-and-ma","article_id":"2625394136","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/881503-main-header/1585186619618"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-csl/csl-shares/news/assessing-csls-valuation-after-us-tariff-reassurances-and-ma","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2625394136","pubTimestamp":1775647944,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. This has eased immediate revenue and margin concerns.\nSee our latest analysis for CSL.\nDespite the reassurance on US tariffs, CSL’s recent share price return shows mixed momentum, with a 1-day gain of 1.33% at A$142.18, a 90-day share price return of 18.50%, and a 1-year total shareholder return...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7508":"医药生物股","BK7501":"新冠治疗股","BK7511":"ESG概念","CSL":"卡莱尔伙伴","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7067":"生物科技","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","CSL.AU":"CSL LIMITED","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4086":"建筑产品","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc"},"translate_title":"评估美国关税保证和制造扩张计划后CSL的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"CSL":1.5,"CSL.AU":1.5},"content_text":"Fresh US import tariff policies have put CSL (ASX:CSL) under the spotlight, with the company telling investors that most US product sales, especially plasma therapies, are expected to remain exempt. This has eased immediate revenue and margin concerns. See our latest analysis for CSL. Despite the reassurance on US tariffs, CSL’s recent share price return shows mixed momentum, with a 1-day gain of 1.33% at A$142.18, a 90-day share price return of 18.50%, and a 1-year total shareholder return of 37.64%. If this tariff news has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 10 healthcare AI stocks CSL now trades at A$142.18 after a 1-year total shareholder return of 37.64%, alongside revenue growth of 4.65% and net income growth of 28.37%. Is this healthcare giant still undervalued, or is the market already pricing in its next phase of growth? AdvertisementMost Popular Narrative: 46% Undervalued According to Ramsee, the most followed narrative on CSL pegs fair value at A$263.33 per share, versus the current A$142.18, using a 4.0% discount rate.  The fair value of CSL is estimated using a Discounted Cash Flow (DCF) approach, which values the company based on the present value of its expected future free cash flows. This methodology is described as appropriate for a company like CSL with a strong market position and relatively predictable, albeit growing, long-term cash flow generation potential.  Read the complete narrative. Curious what kind of revenue runway and profit margins are baked into that outcome, and how tariff scenarios feed into the cash flow curve? The full narrative spells out those moving parts in detail so you can judge how realistic they feel. Result: Fair Value of A$263.33 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this hinges on US trade policy staying pharma friendly and CSL executing on plasma margin recovery, so a tariff shock or operational stumble could quickly challenge it. Find out about the key risks to this CSL narrative. Next Steps With both risks and rewards in play, the key question is how you see the balance right now. Move quickly to review the 3 key rewards and 4 important warning signs Looking for more investment ideas? If CSL is already on your radar, do not stop there. Use the wider market to spot fresh ideas that fit your risk level and income goals.  Target dependable income by scanning companies that show up in the 6 dividend fortresses and see which payouts might suit your portfolio. Hunt for quality at a sensible price by checking stocks in the 7 high quality undervalued stocks before momentum and sentiment move on. Prioritise resilience by reviewing companies highlighted in the 8 resilient stocks with low risk scores so you are not late to steadier opportunities.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2625394136","isCrawlerRequest":true}